U.S. Markets close in 2 hrs 10 mins

These 4 Healthcare Stocks Are Making Moves

CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc (SGYP), Novavax Inc (NVAX), and Epizyme Inc (EPZM) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) opened Friday with the Company's shares trading at $0.63 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from early last month. In December, the Company announced that, as a means of furthering their efforts to develop innovative approaches that combine human-skill based expertise with emerging technologies for the healthcare sector, it had signed a binding letter of intent to acquire all outstanding securities of Cloud Practice Inc.

Presently, Cloud Practice offers cloud-based electronic medal records software for medical professionals across Canada. As stated in their recent financial reports, Cloud Practice is EBITDA positive, resulting in immediate cash flow generation and earnings accretion for Premier Health.

In affirmation of the LOI, Premier Health Group (OTC:PHGRF) (CSE:PHGI)'s CEO, Dr. Essam Hamza, said, ''We are ecstatic at the opportunity to build on our patient centric technology platform through the integration of Cloud Practice's suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare. We believe that this partnership will help facilitate our vision of integrating telemedicine, online booking and other premium services with our electronic medical record (EMR) system.''

For More Information On Premier Health Group, Click Here

Synergy Pharmaceuticals, Inc (SGYP) a biopharmaceutical company that is largely focused on developing originative gastrointestinal therapies, announced in early December that it had entered into an agreement with Bausch Health Companies Inc. through which Bausch Health would acquire substantially all of Synergy's assets, including all rights to TRULANCE®, dolcanatide and related intellectual property, for approximately $200 million in cash.

Troy Hamilton, Chief Executive Officer of Synergy, said, ''We have worked diligently to serve our patients, health care professionals and other stakeholders by bringing TRULANCE® to market and developing other GI therapies to address previously unmet needs. Unfortunately, we have now reached a point where our financial challenges are preventing us from taking this important work to the next level."

For More Information On Synergy Pharmaceuticals, Inc, Click Here

Novavax, Inc (NVAX), in an effort to retain a strong, cohesive leadership team, announced in early December that the Company would be promoting Jill Hoyt to Senior Vice President of Human Resources and Biegie Lee to Vice President of Information Technology.

Stanley Erck, President and CEO of Novavax, said, "I am thrilled to announce these two important management promotions; Jill and Biegie are vital parts of a seasoned executive team striving to accomplish our near and long-term corporate objectives. Jill has been working with me and the senior leadership team to hire, develop and support employees of this company, which is consistently being recognized as one of the best in the biopharmaceutical industry. Biegie has been leading Novavax' efforts to preserve, protect and support our robust IT infrastructure, an important function given our needs around the ongoing management of enormous amounts of data with complex information system tools."

For More Information on Novavax, Inc, Click Here

Epizyme, Inc (EPZM), a clinical-stage company working on developing novel epigenetic therapeutics, announced several pipeline updates on Friday, including that the Company had recently identified a path to submission for accelerated approval of one of their treatments for patients with relapsed and/or refractory follicular lymphoma.

Shefali Agarwal, Chief Medical Officer of Epizyme, said, ''Follicular lymphoma is an incurable cancer today, and in the third line and later settings, there are limited effective treatment options. Defining a clear path to a regulatory submission for tazemetostat for this patient population marks a huge step forward for patients and an opportunity to change the course of FL treatment.''

For More Information On Epizyme, Inc, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 -4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid ''500,000'' shares of restricted common shares (as of 1/4/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information Please click here for full disclaimer.



SOURCE: Stock Price